164513-48-8 Usage
General Description
The chemical "(3-Bromo-4-Methylphenoxy)(tert-butyl)dimethylsilane" is a compound containing a bromine atom, a methyl group, and a phenyl group connected to a silicon atom. It is commonly used as a reagent in organic synthesis reactions, particularly in the formation of carbon-silicon bonds. The tert-butyl and dimethyl groups attached to the silicon atom provide steric hindrance and increase the stability of the compound, making it a valuable reagent for various organic transformations. Additionally, the bromine atom makes it a useful precursor for further functionalization reactions. Overall, this chemical compound plays a significant role in the synthesis of various organic compounds in chemical research and industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 164513-48-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,4,5,1 and 3 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 164513-48:
(8*1)+(7*6)+(6*4)+(5*5)+(4*1)+(3*3)+(2*4)+(1*8)=128
128 % 10 = 8
So 164513-48-8 is a valid CAS Registry Number.
164513-48-8Relevant articles and documents
ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS
-
Paragraph 0050, (2013/09/12)
Provided are analgesic compounds, and salts thereof, of formula: (I) wherein A is: (A) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.
ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS
-
Page/Page column 16-17, (2012/08/08)
Provided are analgesic compounds, and salts thereof, of formula: ( I ) wherein A is: ( A ) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.
INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
-
Page/Page column 48, (2012/12/13)
The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
